Engineering structural bone allografts for enhanced repair and reconstruction
工程结构同种异体骨移植以增强修复和重建
基本信息
- 批准号:9978190
- 负责人:
- 金额:$ 16.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-17 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AllograftingAutologous TransplantationBiocompatible MaterialsBiological AssayBone GrowthBone Marrow Stem CellBone RegenerationBone SurfaceBone TissueBone TransplantationBone callusBone structureCadaverCell LineCell TransplantationCellsChondrocytesClinicalCollaborationsDataDefectDependovirusDepositionDoseEngineeringEngraftmentFailureFibroblastsFibrosisFormulationFractureHistologyHydrogelsImmunohistochemistryImpairmentImplantInfectionLiteratureLuciferasesMechanicsMediatingMedical DeviceMembraneMethodologyMethodsModelingModificationMusOrgan TransplantationOsseointegrationOsteoblastsOsteogenesisPathway interactionsPeptidesPerformancePharmaceutical PreparationsPolymersProcessProductionPropertyRegulationReporterReportingResearchRoleSafetySignal PathwaySignal TransductionStructureSurfaceTGF Beta Signaling PathwayTestingTissuesTorsionTransforming Growth Factor alphaTransforming Growth Factor betaTransplantationUnited StatesVascularizationViral VectorVirusallogenic bone transplantationbasebonebone engineeringbone healingbone morphogenetic protein 2bone morphogenic proteinbone xenograftcombatcontrolled releasehealingimmunoreactionimprovedin vivoin vivo evaluationinhibitor/antagonistinsightmacrophagemicroCTmuscle regenerationnanofibernovelnovel strategiesoperationosteoblast differentiationosteogenicreconstructionrepairedresponsescaffoldsuccesssurface coatingtissue regenerationvector
项目摘要
PROJECT SUMMARY
Bone grafting procedures number over 500,000 annually in the United States, with allograft
tissues used for 33% of the bone grafting operations. Although bone allografts from cadavers
and donors have been utilized extensively to repair bone defects, bone allografts have not
achieved the similar level of efficacy as compared with bone autografts. Furthermore, bone
allografts for treatment of critical-sized bone defects show extremely slow engraftment and ≈
60% long-term failure rates due to fibrotic nonunions, poor vascularization, poor
osteointegration, infections, and microcrack propagation. To improve the healing and
integration, strategies have been developed to modify bone allografts to enhance their
osteogenic and angiogenic properties. These strategies include coating with polymers with and
without incorporation of different drugs, coating with adeno-associated virus – bone
morphogenetic protein 2 (AAV-BMP2) vectors, coating with hydrogels containing bone marrow
stem cells (BMSCs), wrapping with BMSCs-seeded nanofiber membranes. However, these
strategies are associated with many problems including i) fibrosis tissue formation, ii)
involvement of living cells, iii) uneven callus formation, and iv) safety of virus vectors. Therefore,
there is an urgent need to engineer off-the-shelf bone allografts to improve their efficacy and
performance in repair of the critical-sized bone defects. The primary objective of this study is to
engineer bone allografts with a novel coating capable of releasing anti-fibrotic agents and bone
growth regulating factors in either simultaneous or sequential fashion to improve the healing and
osteointegration. To test the hypothesis and accomplish the primary objective, our strategy
includes: i) Establish a method of engineering bone allograft with incorporation of BMP-2
peptides and a TGF-β signaling inhibitor to the coatings; and ii) Assess the anti-fibrotic efficacy,
new bone formation, and osseointegration of engineered bone allografts in a murine femoral
defect model; and 3) Examine the antagonism between TGF-β and BMP-2 signaling during
bone allograft repair. We expect to identify the role of anti-fibrotic agents and bone growth
regulatory factors on the healing of a critical bone defect through surface engineered bone
allografts. The proposed strategy could also be useful in various applications aimed at
promoting tissue regeneration.
项目摘要
在美国,每年有超过500,000例骨移植手术,
用于33%的骨移植手术的组织。虽然尸体上的同种异体骨
并且供体已被广泛用于修复骨缺损,骨同种异体移植物还没有
与自体骨移植相比,达到了相似的疗效水平。此外,骨
用于治疗临界大小骨缺损的同种异体移植物显示出极慢的植入和坏死,
60%的长期失败率是由于纤维化不愈合、血管化不良、
骨整合、感染和微裂纹扩展。为了改善愈合,
整合,已经开发了策略来修饰骨同种异体移植物,以增强其
成骨和血管生成特性。这些策略包括用聚合物涂覆,
不掺入不同的药物,用腺相关病毒包被-骨
形态发生蛋白2(AAV-BMP 2)载体,用含有骨髓的水凝胶包被
干细胞(BMSCs),用BMSCs接种的生物膜包裹。但这些
策略与许多问题相关,包括i)纤维化组织形成,ii)
活细胞的参与,iii)不均匀的愈伤组织形成,和iv)病毒载体的安全性。因此,我们认为,
迫切需要设计现成的骨同种异体移植物以提高它们的功效,
关键尺寸骨缺损的修复性能。本研究的主要目的是
具有能够释放抗纤维化剂和骨的新型涂层的工程化骨同种异体移植物
以同时或顺序的方式施用生长调节因子以改善愈合,
骨整合为了验证假设并实现主要目标,我们的策略
包括:i)建立BMP-2诱导的同种异体骨工程化方法
肽和TGF-β信号传导抑制剂;和ii)评估抗纤维化功效,
小鼠股骨中工程化同种异体骨的新骨形成和骨整合
缺陷模型;和3)检查在骨缺损期间TGF-β和BMP-2信号传导之间的拮抗作用。
同种异体骨移植修复我们希望确定抗纤维化药物和骨生长的作用
表面工程骨修复严重骨缺损的调控因素
同种异体移植所提出的策略还可以用于各种应用,
促进组织再生。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jingwei Xie其他文献
Jingwei Xie的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jingwei Xie', 18)}}的其他基金
Multifunctional Intelligent Hierarchical Fibrous Biomaterials Integrated with Multimodal Biosensing and Feedback-Based Interventions for Healing Infected Chronic Wounds
多功能智能分层纤维生物材料与多模式生物传感和基于反馈的干预措施相结合,用于治愈感染的慢性伤口
- 批准号:
10861531 - 财政年份:2023
- 资助金额:
$ 16.86万 - 项目类别:
Strategies to Enhance Engineered Heart Tissue Based Myocardial Repair
增强基于工程心脏组织的心肌修复的策略
- 批准号:
10581419 - 财政年份:2023
- 资助金额:
$ 16.86万 - 项目类别:
A Novel High-Intensity Iontophoresis-Based Antibiotic Delivery Device for Efficacious Eradication of Chronic Wound Biofilms
一种新型高强度离子电渗疗法抗生素输送装置,可有效根除慢性伤口生物膜
- 批准号:
10433163 - 财政年份:2022
- 资助金额:
$ 16.86万 - 项目类别:
A Novel High-Intensity Iontophoresis-Based Antibiotic Delivery Device for Efficacious Eradication of Chronic Wound Biofilms
一种新型高强度离子电渗疗法抗生素输送装置,可有效根除慢性伤口生物膜
- 批准号:
10634602 - 财政年份:2022
- 资助金额:
$ 16.86万 - 项目类别:
Biomimetic and Injectable Highly Porous Nanofiber Microsphere-based Platform for Alveolar Bone Regeneration
用于牙槽骨再生的仿生和可注射高孔隙纳米纤维微球平台
- 批准号:
10641000 - 财政年份:2022
- 资助金额:
$ 16.86万 - 项目类别:
Nanofiber-based Delivery of Combined Immune-modulating Compounds to Minimize Infection and Enhance Wound Healing
基于纳米纤维的组合免疫调节化合物的递送以最大程度地减少感染并促进伤口愈合
- 批准号:
10473866 - 财政年份:2017
- 资助金额:
$ 16.86万 - 项目类别:
Nanofiber-based Delivery of Combined Immune-modulating Compounds to Minimize Infection and Enhance Wound Healing
基于纳米纤维的组合免疫调节化合物的递送以最大程度地减少感染并促进伤口愈合
- 批准号:
10653967 - 财政年份:2017
- 资助金额:
$ 16.86万 - 项目类别:
Nanofiber-based Delivery of Combined Immune-modulating Compounds to Minimize Infection and Enhance Wound Healing
基于纳米纤维的组合免疫调节化合物的递送以最大程度地减少感染并促进伤口愈合
- 批准号:
10299094 - 财政年份:2017
- 资助金额:
$ 16.86万 - 项目类别:
Nanofiber-based Delivery of Combined Immune-modulating Compounds to Minimize Infection and Enhance Wound Healing
基于纳米纤维的组合免疫调节化合物的递送以最大程度地减少感染并促进伤口愈合
- 批准号:
10796228 - 财政年份:2017
- 资助金额:
$ 16.86万 - 项目类别:
相似海外基金
Precision genome editing with tandem autologous transplantation as a therapy for multiple severe immune-mediated diseases
精准基因组编辑与串联自体移植治疗多种严重免疫介导疾病
- 批准号:
MR/T030410/1 - 财政年份:2021
- 资助金额:
$ 16.86万 - 项目类别:
Research Grant
Osteochondral regeneration by autologous transplantation of abundant stem cells cultured high-densely
通过高密度培养的丰富干细胞自体移植实现骨软骨再生
- 批准号:
19H03129 - 财政年份:2019
- 资助金额:
$ 16.86万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development and research of function maintenance culture method and new autologous transplantation method of human salivary gland cells
人唾液腺细胞功能维持培养方法及自体移植新方法的开发研究
- 批准号:
19K19186 - 财政年份:2019
- 资助金额:
$ 16.86万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Investigation of tissue architecture of abdominal wall endometriosis for ovarian autologous transplantation to abdominal wall
腹壁子宫内膜异位症腹壁自体卵巢移植的组织结构研究
- 批准号:
18K09266 - 财政年份:2018
- 资助金额:
$ 16.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
autologous transplantation of adipose tissue derived mesenchymal stromal cells to the old myocardial infarction heart
自体脂肪组织间充质干细胞移植至陈旧性心肌梗死心脏
- 批准号:
18K15839 - 财政年份:2018
- 资助金额:
$ 16.86万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of heart regenerative therapy for old myocardial infarction by autologous transplantation with iPSC-derived cardiomyocytes
利用iPSC来源的心肌细胞自体移植治疗陈旧性心肌梗死的心脏再生疗法的进展
- 批准号:
17K16589 - 财政年份:2017
- 资助金额:
$ 16.86万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Development of a regenerative therapy for spinal cord injury by autologous transplantation of bone marrow derived mononuclear cell.
通过骨髓来源的单核细胞自体移植开发脊髓损伤再生疗法。
- 批准号:
24580469 - 财政年份:2012
- 资助金额:
$ 16.86万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Autologous transplantation of conjunctival epithelial stem cells based on epigenetical control.
基于表观遗传控制的结膜上皮干细胞自体移植。
- 批准号:
24659757 - 财政年份:2012
- 资助金额:
$ 16.86万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Basic study of autologous transplantation of ex vivo expanding macrophages to secondary lymphedema
离体扩增巨噬细胞自体移植治疗继发性淋巴水肿的基础研究
- 批准号:
23791286 - 财政年份:2011
- 资助金额:
$ 16.86万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
PRIMATE PLURIPOTENT CELLS FOR AUTOLOGOUS TRANSPLANTATION
用于自体移植的灵长类多能细胞
- 批准号:
8173333 - 财政年份:2010
- 资助金额:
$ 16.86万 - 项目类别: